SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Inari Medical, Inc. (NARI) , forward earnings yield 0.60%. PEG 2.25.
Criteria proven by this page:
- VALUE (20/100, Fail) — analyst consensus target implies downside from the current price ($67.56, 15.5%); PEG > 2.0 means the stock is expensive even after accounting for growth (PEG 2.25).
- Forward P/E 167.0
- PEG Ratio 2.25 — above 2.0 suggests expensive relative to earnings growth.
- Analyst consensus target $67.56 (-15.5% downside) — analysts see meaningful downside risk at the current price level.
Overall SharesGrow Score: 40/100 with 0/7 criteria passed.
SharesGrow 7-Criteria Score
✗
VALUE
20/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — NARI
Valuation Multiples
P/E (TTM)0.0
Forward P/E167.0
PEG Ratio2.25
Forward PEG2.25
P/B Ratio0.00
P/S Ratio9.20
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-0.03
Forward EPS (Est.)$0.48
Book Value / Share$0.00
Revenue / Share$8.70
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Forward Earnings Yield0.60%
Dividend Yield0.00%
Analyst Target$67.56 (-15.5%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2018 |
$-0.23 |
$6.83M |
$-10.15M |
-148.7% |
| 2019 |
$-0.04 |
$51.13M |
$-1.91M |
-3.7% |
| 2020 |
$0.27 |
$139.67M |
$13.79M |
9.9% |
| 2021 |
$0.18 |
$276.98M |
$9.84M |
3.6% |
| 2022 |
$-0.55 |
$383.47M |
$-29.27M |
-7.6% |
| 2023 |
$-0.03 |
$493.63M |
$-1.64M |
-0.3% |
